Table 2.
T0 (baseline) |
T1 (week 1) |
T2 (week 2) |
ANCOVA between group |
||
---|---|---|---|---|---|
ΔT0-T1 | ΔT0-T2 | ||||
Mean ± SD | Mean ± SD | Mean ± SD | F/p-value‡ (pη2) | F/p-value‡ (pη2) | |
Primary outcomes | |||||
MDS-UPDRS part III scores | |||||
Total score† | |||||
INSTR | 38.4 ± 11.4 | 28.8 ± 8.9** | 23.1 ± 10.3** | 5.4/0.033* (0.241) | 11.4/0.004** (0.401) |
Control | 39.0 ± 13.6 | 32.4 ± 12.2** | 28.1 ± 11.2** | ||
Tremor subscore† | |||||
INSTR | 2.9 ± 2.6 | 1.7 ± 2.2* | 1.5 ± 1.5* | 0.1/0.808 (0.004) | 0.5/0.477 (0.030) |
Control | 2.0 ± 2.0 | 1.0 ± 1.5 | 0.8 ± 1.2 | ||
Rigidity subscore† | |||||
INSTR | 8.9 ± 3.7 | 7.7 ± 3.4* | 6.9 ± 3.1* | 0.2/0.689 (0.010) | 0.2/0.634 (0.014) |
Control | 8.2 ± 3.5 | 7.3 ± 3.1* | 6.7 ± 3.0* | ||
Bradykinesia subscore† | |||||
INSTR | 18.6 ± 5.0 | 14.5 ± 4.4** | 11.5 ± 5.8** | 2.1/0.170 (0.108) | 0.8/0.384 (0.045) |
Control | 19.8 ± 8.6 | 16.8 ± 7.3* | 13.6 ± 7.1** | ||
Axial subscore† | |||||
INSTR | 8.0 ± 2.8 | 4.9 ± 2.6** | 3.2 ± 2.2** | 5.0/0.040* (0.226) | 16.9/< 0.001*** (0.498) |
Control | 9.0 ± 2.5 | 7.3 ± 3.3* | 7.0 ± 3.1** | ||
Pull test† | |||||
INSTR | 2.7 ± 0.7 | 1.0 ± 1.2* | 0.1 ± 0.3** | 1.5/0.231 (0.083) | 12.3/0.003** (0.419) |
Control | 2.4 ± 0.8 | 1.5 ± 1.4* | 1.4 ± 1.3* | ||
Secondary outcomes | |||||
TUG (s)† | |||||
INSTR | 17.86 ± 9.23 | 13.02 ± 6.10** | 12.12 ± 5.48** | 1.5/0.239 (0.081) | 0.1/0.744 (0.006) |
Control | 18.84 ± 10.89 | 15.66 ± 7.77 | 13.10 ± 5.68* | ||
Fast walking speed (m/s)† | |||||
INSTR | 0.89 ± 0.28 | 1.10 ± 0.38* | 1.22 ± 0.34** | 1.0/0.341 (0.054) | 1.9/0.188 (0.100) |
Control | 0.90 ± 0.30 | 1.04 ± 0.34 | 1.10 ± 0.43 | ||
Barthel Index† | |||||
INSTR | 82.5 ± 10.6 | – | 92.5 ± 10.6* | – | 1.4/0.248 (0.078) |
Control | 78.0 ± 14.2 | – | 85.5 ± 12.6* |
Abbreviations: ANCOVA, analysis of covariance; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; TUG, timed up and go.
†Significance levels of *p < 0.05 and **p < 0.01 in intragroup comparisons (T0 vs. T1 or T0 vs. T2) using the Wilcoxon signed-rank test.
‡Significance levels of *p < 0.05, **p < 0.01, ***p < 0.001 in ANCOVA.